Navigation Links
Amarin Reports Top-Line Results of two Phase III Studies of,Miraxion in Huntington's Disease

Conference Call Begins Today at 11:00 a.m. Eastern Time

LONDON, April 24, 2007 /PRNewswire-FirstCall/ -- Amarin Corporation plc ("Amarin" or the "Company") today announces top-line results from its two Phase III clinical trials of Miraxion to treat Huntington's disease (HD). The Company conducted two Phase III double-blind, placebo-controlled studies in which HD patients were randomized to receive either placebo or 2 grams (1 gram twice daily) of Miraxion daily for six months. Study data showed no statistically significant difference in either study between Miraxion and placebo with regard to the primary and secondary endpoints.

These top-line findings are inconsistent with earlier clinical trial data that showed statistical significance in a subset of HD patients with a CAG repeat length of less than or equal to 44.

The primary endpoint of the trials was a change in the Total Motor Score 4 (TMS-4) component of the Unified Huntington's Disease Rating Scale (UHDRS). TMS-4 has been shown to be a sensitive measure of movement disorder in patients with HD. In addition, secondary endpoints included cognition and Total Functional Capacity outcomes. Miraxion was found to be safe and well-tolerated by patients.

Commenting on today's announcement, Rick Stewart, Chief Executive Officer of Amarin, said, "We are extremely surprised and disappointed by these top-line results, and we are analyzing the data in order to better understand the full and complete data set and outcomes. We are particularly disappointed that, at this time, we are not in a position to bring any positive news to those patients who are suffering from this devastating disease and to the broader HD community."

"Despite this setback with Miraxion to treat HD, we remain committed to developing Amarin's substantial central nervous system (CNS) development pipeline." commented Mr. Stewart. "We continue to evaluate the potential of
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:12/16/2009)... Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), ... non-human primate study of its novel, once-a-day, oral ... of tularemia. A 14-day course of Restanza achieved ... All of the ten animals in the ... (approximate to a human dose of 300 mg) ...
(Date:12/16/2009)... -- , - ... a Total of Over,640 patients Ahead of ... NV (Euronext Brussels: THR), a biopharmaceutical company,focused ... treatments for eye,disease, vascular disease and cancer, ... of the second Phase III trial evaluating ...
(Date:12/15/2009)... Cellular Dynamics International ... iCell(TM) Cardiomyocytes for use in testing of new ... human heart cells are designed to aid drug ... efficacy and toxicity screens, weeding out ineffective and ... process before significant time and resources have been ...
Breaking Medicine Technology:Advanced Life Sciences' Restanza Shows 100% Survival in Tularemia Pivotal Animal Study 2Advanced Life Sciences' Restanza Shows 100% Survival in Tularemia Pivotal Animal Study 3Advanced Life Sciences' Restanza Shows 100% Survival in Tularemia Pivotal Animal Study 4ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 2ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 3ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 4Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening 2Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening 3Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening 4Tis the Season to Eat and Eat More 21 61910 1Tis the Season to Eat and Eat More 21 61910 2New research shows versatility of amniotic fluid stem cells 61908 1New research shows versatility of amniotic fluid stem cells 61908 2Moravia Worldwide Names George Krawczyk as Sales Director for Ireland and UK 61905 1Moravia Worldwide Names George Krawczyk as Sales Director for Ireland and UK 61905 2
(Date:12/16/2009)... be determining factor for use, expert says, , , WEDNESDAY, ... failure are much less likely to die when they ... , The study included 4,685 people, ages 65 to ... a left ventricular fraction (a measure of the heart,s ... a three-year period, those who were treated with standard ...
(Date:12/16/2009)... Shoppers like knowing if their salad ... But grocers have found it burdensome to implement ... requiring them to provide the information at point ... easyCOOLnow.com for easily making grocery and produce ... that require retailers of unprocessed fruits, vegetables and ...
(Date:12/16/2009)... A new software program developed by CareRise ... facilities to calculate their staffing needs as it relates ... allows inpatient healthcare facilities to calculate their mandatory nurse-to-patient ... and receive a daily report as to how it ... leader in risk management in the healthcare industry, has ...
(Date:12/16/2009)... a random sampling of wood pallets used to ... numerous pallets tested positive for Listeria and abnormally ... health hazards for consumers. The new data ... conducted in the Washington-Baltimore area, further illustrating the ... food supply from wood pallets. ,, The new ...
(Date:12/16/2009)... procedures in cardiology. The idea of publishing an ESC ... European cardiovascular imagers, is therefore long awaited. The textbook ... a patient rather than technology-based approach, helping clinicians to ... of imaging. , The book is divided into ... of cardiac imaging and its clinical use in all ...
Breaking Medicine News(10 mins):Health News:Implanted Defibrillator Might Extend Life 2Health News:New Website Helps Grocers Comply With COOL Laws 2Health News:United States Patent Office Allows CareRise Patent on 24/7 Staff-Census Software 2Health News:New Tests Confirm Wood Pallets Harbor Deadly Food Poisoning Bacteria 2Health News:New Tests Confirm Wood Pallets Harbor Deadly Food Poisoning Bacteria 3Health News:New Tests Confirm Wood Pallets Harbor Deadly Food Poisoning Bacteria 4Health News:The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center 2Health News:The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center 3
... treatment for non-cancer health issues while being treated by ... a study published in the December 20 issue of ... by researchers from the Indiana University School of Medicine, ... Center, is the first to look at the effect ...
... EL SEGUNDO, Calif., Dec. 27 Computer ... that it has signed an extension to,a ... with Sun Microsystems Inc., Under the ... all,applications development and support services for Sun,s ...
... Women Urged to Take Action and Protect Themselves in ... Approximately,10,000 American women will learn they have cervical cancer/HPV ... form of the disease. This,January, during Cervical Health Awareness ... educating women about the importance,of the Pap test as ...
... While Preserving Choice, SACRAMENTO, Calif., Dec. 26 ... largest non-government HIV testing,program in California, today offered ... signed into law yesterday in New Jersey by ... routine testing of pregnant,women and some newborns for ...
... Inhibiting the growth of blood vessels that supply ... according to results of a large clinical trial ... in the December 27th issue of the New ... combination with chemotherapy significantly prolongs progression-free survival for ...
... to halting of cancer therapy, report says , , WEDNESDAY, ... for prostate cancer who take baby aspirin to protect ... new research suggests. , Apparently, baby aspirin interacts with ... end result is the man must stop potentially lifesaving ...
Other Medicine News:Health News:Treating oft ignored non-cancer health issues after cancer diagnosis prolongs survival 2Health News:CSC Signs Extension to Managed Applications Services Agreement With Sun Microsystems 2Health News:National Cervical Cancer Coalition Stresses Importance of Screening and Prevention During January Cervical Health Awareness Month 2Health News:AHF Says 'Op-Out' Clause is Crucial to New Jersey Law Requiring HIV Testing of Pregnant Women 2Health News:AHF Says 'Op-Out' Clause is Crucial to New Jersey Law Requiring HIV Testing of Pregnant Women 3Health News:Bevacizumab found to improve survival for patients with advanced breast cancer 2Health News:Aspirin, Hormone Therapy Combo Can Shorten Lives of Prostate Cancer Patients 2Health News:Aspirin, Hormone Therapy Combo Can Shorten Lives of Prostate Cancer Patients 3
Mounted on an extremely lightweight,and flexible cotton headband, the,Halogen III Sport adjusts around the head,and the crown strap for a comfortable and secure fit....
Mounted on a fully adjustable molded,headband with crown strap and comfort,cushions, the sturdy Halogen III Classic is,lightweight, comfortable and durable....
Mounted on a remarkably lightweight and,flexible cotton headband with crown strap,the Sport is fully adjustable....
... With its simplified operations, the ... patient, clinic or satellite lab testing. ... offers multi-language software. Built on ... technology, the KX-21N features a completely ...
Medicine Products: